Publications by authors named "Donna Ryan"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

18,837

Total Likes

2,019

Extended Reach

7,061,557

Social Features

523
O
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
Deborah B Horn, Donna H Ryan, Sanja Giljanovic Kis, Breno Alves, Yiming Mu

Lancet· December 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of the Early Response to an Oral Shape-Shifting Superabsorbent Hydrogel Capsule With Weight Loss.
John M Jakicic, Donna H Ryan, Jamy D Ard, Patrick M O'Neil, Robert F Kushner

Clin Obes· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety and efficacy of extended use of an oral shape-shifting superabsorbent hydrogel capsule for weight loss: The ELECT extension study.
Moshe Kamar, Donna H Ryan, Sharon Leonard, Holly R Wyatt, Yael Kenan

Obes Pillars· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. Reply.
Ania M Jastreboff, Donna H Ryan, Nicola Pannacciulli

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.
Stephen J Nicholls, Donna H Ryan, John Deanfield, Daniel Ferreira, Chim C Lang

JAMA Cardiol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and Future Medications for Obesity Treatment.
Robert F Kushner, Ania M Jastreboff, Donna H Ryan

JAMA· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision Prevention, Diagnostics, and Treatment of Obesity: Pipedream or Reality?
Emily K Woolf, Hanim E Diktas, Andres Acosta, John W Apolzan, Jamy D Ard, Donna H Ryan

Obesity (Silver Spring)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
John Deanfield, A Michael Lincoff, Steven E Kahn, Scott S Emerson, Ildiko Lingvay, Donna H Ryan

Lancet· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?
Donna H Ryan

Rev Endocr Metab Disord· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.
Ania M Jastreboff, Donna H Ryan, Harold E Bays, Peter R Ebeling, Mia G Mackowski

N Engl J Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life improvements associated with weight loss using a novel shape-shifting hydrogel capsule: RESET study results.
Robert F Kushner, Jamy D Ard, Thomas A Wadden, Patrick M O'Neil, Harold E Bays, Donna H Ryan

Int J Obes (Lond)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond Obesity.
George A Bray, Donna H Ryan

Med Sci (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to "Weight-loss drugs like Wegovy could lead to an increased risk of fragility fractures in population at risk".
Robert F Kushner, Donna H Ryan, Nina M Harder-Lauridsen, Ole Kleist Jeppesen, Klaus Kallenbach

Obesity (Silver Spring)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucagon-like peptide-1 receptor agonists lower risk of cardiovascular and non-cardiovascular mortality: A meta-analysis of eleven cardiovascular outcome trials.
Yu Mi Kang, Erin A Bohula, A Michael Lincoff, Donna H Ryan, KyungAh Im

Diabetes Obes Metab· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of a novel oral hydrogel capsule in adults with overweight or obesity: the pivotal randomized RESET study.
Jamy D Ard, Donna H Ryan, Patrick M O'Neil, Robert F Kushner, Holly R Wyatt

Obesity (Silver Spring)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial.
Robert F Kushner, Donna H Ryan, John Deanfield, Alexander Kokkinos, Cintia Cercato

Obesity (Silver Spring)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.
Steven E Kahn, John E Deanfield, Ole Kleist Jeppesen, Scott S Emerson, Trine Welløv Boesgaard, Donna H Ryan

Diabetes Care· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.
Ildiko Lingvay, John Deanfield, Steven E Kahn, Peter E Weeke, Hermann Toplak, Donna Ryan

Diabetes Care· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
John Deanfield, Subodh Verma, Benjamin M Scirica, Steven E Kahn, Scott S Emerson, Donna Ryan

Lancet· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease.
A Michael Lincoff, Donna H Ryan

Eur Heart J Cardiovasc Pharmacother· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semaglutide and Cardiovascular Outcomes. Reply.
A Michael Lincoff, Donna H Ryan, Sille Esbjerg

N Engl J Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of an oral biodegradable device used for 12 weeks on weight reduction, cardiovascular risk factors, satiety, snacking, and meal size.
Haim Shirin, Ian J Neeland, Donna H Ryan, Daniel de Luis, Albert Lecube

Obes Pillars· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis